Every material Form 8-K Mereo BioPharma Group plc has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
Mereo BioPharma Group plc was told by Nasdaq that it has not yet regained the $1.00 minimum bid price required for continued listing, but it qualifies for an additional 180-day period, running to February 16, 2027. The notice has no immediate effect on the listing of its American Depositary Shares, though a failure to regain compliance by then would lead to a delisting notice that the company could appeal.
Nasdaq's first notice, dated February 17, 2026, set an initial compliance deadline of August 17, 2026.
On August 18, 2026, Nasdaq issued a second notice granting an additional 180 calendar days, until February 16, 2027.
Regaining compliance requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
The company says the listing is unaffected for now and that it may consider options to regain compliance.
Mereo BioPharma reported second-quarter 2026 results with a net loss of $7.0 million, down from $14.6 million a year earlier, and revenue of zero versus $0.5 million in the prior-year quarter. The company also signed an option and license agreement with Sentynl Therapeutics for alvelestat, and said its cash of $30.1 million should fund operations into late 2027, while setrusumab's Phase 3 studies missed their primary endpoints.
Q2 2026 net loss was $7.0 million, compared with $14.6 million in Q2 2025; revenue was zero versus $0.5 million a year earlier.
Cash and cash equivalents were $30.1 million at June 30, 2026, down from $41.0 million at December 31, 2025, and are expected to fund operations into late 2027.
Sentynl can exercise an option to license alvelestat; on exercise Mereo would be eligible for $40 million in upfront and R&D payments and up to $435 million in milestones.
Orbit and Cosmic Phase 3 studies of setrusumab did not meet the primary fracture-rate endpoints; Mereo and Ultragenyx expect a regulatory path update by year-end 2026.
Mereo BioPharma entered into an Option and License Agreement with Sentynl Therapeutics on August 11, 2026, covering U.S. commercial rights and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo keeps rest-of-world rights and will lead the global Phase 3 study, with the companies refining the study design during the option period. For shareholders, the deal provides for a non-refundable option fee and, on option exercise, $40 million in upfront and R&D payments plus up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales, though these payments depend on Sentynl exercising the option.
Sentynl gets the option to license U.S. commercialization of alvelestat; Mereo keeps rest-of-world rights and leads global Phase 3 development
On option exercise, Mereo is eligible to receive $40 million in upfront and R&D payments
Mereo is also eligible for up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales
The agreement is dated August 11, 2026; the full agreement is expected to be filed with the 10-Q for the quarter ending September 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Mereo BioPharma Group plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →